The influence of conservative surgical practices for malignant ovarian germ cell tumors

被引:76
|
作者
Chan, John K. [1 ]
Tewari, Krishnansu S. [2 ]
Waller, Sarah [3 ]
Cheung, Michael K. [1 ]
Shin, Jacob Y. [1 ]
Osann, Kathryn [4 ]
Kapp, Daniel S. [5 ]
机构
[1] Univ Calif San Francisco, Sch Med, Dept Obstet Gynecol & Reprod Sci, Div Gynecol Oncol,UCSF Helen Diller Family Compre, San Francisco, CA 94143 USA
[2] Univ Calif Irvine, Irvine Med Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Orange, CA 92668 USA
[3] Stanford Univ, Sch Med, Stanford Canc Ctr, Dept Obstet & Gynecol,Div Gynecol Oncol, Stanford, CA 94305 USA
[4] Univ Calif Irvine, Irvine Med Ctr, Chao Family Comprehens Canc Ctr, Dept Med,Div Hematol & Oncol, Orange, CA 92668 USA
[5] Stanford Univ, Sch Med, Stanford Canc Ctr, Div Radiat Therapy,Dept Radiat Oncol, Stanford, CA 94305 USA
关键词
germ cell tumors; ovarian cancer; surgical practice;
D O I
10.1002/jso.21079
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To evaluate demographics, survival, and surgical trends for patients with malignant ovarian germ cell tumors. Methods: SEER data abstracted from 1988 to 2001 and analyzed using Kaplan-Meier and Cox regression models. Results: Of 760 patients, the median age was 23 years. Seventy-six percent of patients presented with stage I-II disease, and 24% with stage III-IV. Fifty-five percent were immature teratomas, 32% dysgerminomas, and 13% yolk sac tumors. Fertility-preserving surgery was performed in 41.2% (n = 313) of patients. In those <45 years old, the use of fertility-preserving surgery increased from 40.5% to 44.5% to 48.4% over the time periods 1988-1992, 1993-1997, 1998-2001 (P = 0.25). The survival of patients who underwent fertility-preserving surgery was not statistically different compared to those who underwent standard surgery (P = 0.26). Patients with stage I-II disease had improved survival compared to stage III-IV disease (97.6% vs. 85.5%, P < 0.001). The overall survival of women with dysgerminomas, immature teratomas, and yolk sac tumors was 99.5%, 94.3%, and 85.4%, respectively (P < 0.001). In multivariate analysis, older age, advanced stage, and yolk sac tumor histology predicted for poorer survival. Conclusion: Our data suggests that the use of fertility-preserving surgery with concomitant surgical staging for germ cell cancers has increased without compromising survival.
引用
收藏
页码:111 / 116
页数:6
相关论文
共 50 条
  • [31] Contemporary management of ovarian germ cell tumors and remaining controversies
    Veneris, Jennifer Taylor
    Mahajan, Priya
    Frazier, A. Lindsay
    GYNECOLOGIC ONCOLOGY, 2020, 158 (02) : 467 - 475
  • [32] Clinicopathological Features, Prognostic Factors, Survival Trends, and Treatment of Malignant Ovarian Germ Cell Tumors: A SEER Database Analysis
    Guo, Hualei
    Chen, Hao
    Wang, Wenhui
    Chen, Lingna
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (04) : 145 - 152
  • [33] Surveillance alone in stage I malignant ovarian germ cell tumors: a MITO (Multicenter Italian Trials in Ovarian cancer) prospective observational study
    Mangili, Giorgia
    Giorda, Giorgio
    Ferrandina, Gabriella
    Cormio, Gennaro
    Cassani, Chiara
    Savarese, Antonella
    Danese, Saverio
    Carnelli, Marco
    Vasta, Francesca Maria
    Perrone, Anna Myriam
    Scarfone, Giovanna
    Pignata, Sandro
    Legge, Francesco
    Raspagliesi, Francesco
    Taccagni, Gianluca
    Candiani, Massimo
    Bogani, Giorgio
    Mascilini, Floriana
    Bergamini, Alice
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 (09) : 1242 - 1247
  • [34] Performance of lymphadenectomy for apparent early stage malignant ovarian germ cell tumors in the era of platinum-based chemotherapy
    Nasioudis, Dimitrios
    Ko, Emily M.
    Haggerty, Ashley F.
    Cory, Lori
    Giuntoli, Robert L., II
    Burger, Robert A.
    Morgan, Mark A.
    Latif, Nawar A.
    GYNECOLOGIC ONCOLOGY, 2020, 157 (03) : 613 - 618
  • [35] Recommendations of the Fertility Task Force of the European Society of Gynecologic Oncology About the Conservative Management of Ovarian Malignant Tumors
    Morice, Philippe
    Denschlag, Dominik
    Rodolakis, Alex
    Reed, Nick
    Schneider, Achim
    Kesic, Vesna
    Colombo, Nicoletta
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2011, 21 (05) : 951 - 963
  • [36] Risk of second malignant neoplasms in women and girls with germ cell tumors
    Liao, Z.
    Rodrigues, M. C.
    Poynter, J. N.
    Amatruda, J. F.
    Rodriguez-Galindo, C.
    Frazier, A. L.
    ANNALS OF ONCOLOGY, 2017, 28 (02) : 329 - 332
  • [37] Treatment of nondysgerminomatous ovarian germ cell tumors - An analysis of 69 cases
    Mitchell, PL
    Al-Nasiri, N
    A'Hern, R
    Fisher, C
    Horwich, A
    Pinkerton, CR
    Shepherd, JH
    Gallagher, C
    Slevin, M
    Harper, P
    Osborne, R
    Mansi, J
    Oliver, T
    Gore, ME
    CANCER, 1999, 85 (10) : 2232 - 2244
  • [38] Therapeutic Challenges for Cisplatin-Resistant Ovarian Germ Cell Tumors
    De Giorgi, Ugo
    Casadei, Chiara
    Bergamini, Alice
    Attademo, Laura
    Cormio, Gennaro
    Lorusso, Domenica
    Pignata, Sandro
    Mangili, Giorgia
    CANCERS, 2019, 11 (10)
  • [39] Histological and immunohistochemical features of the ovarian malignant epithelial tumors and granulosa cell tumors
    Savchenko, O. A.
    Shponka, I. S.
    Skoryk, V. R.
    Savchenko, P., V
    PATHOLOGIA, 2019, (02): : 155 - 163
  • [40] Pregnancy outcome after prenatal exposure to bleomycin, etoposide and cisplatin for malignant ovarian germ cell tumors: report of 2 cases
    Han, JY
    Nava-Ocampo, AA
    Kim, TJ
    Shim, JU
    Park, CT
    REPRODUCTIVE TOXICOLOGY, 2005, 19 (04) : 557 - 561